• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Spark slides on hemophilia A data, aims for phase 3 fiercebiotech
    August 08, 2018
    Spark Therapeutics’ hemophilia A gene therapy reduced bleeding by 97% in a phase 1/2 trial, building on data reported in December that suggested it may not be as potent as a rival in development at BioMarin.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service